Food and Drug Administration officials are unhappy about the proliferation of ads for prescription drugs that minimize risk information, hype benefits, make unsupported claims and even fail to acknowledge serious product warnings.
Washington, D.C. - Food and Drug Administration officials are unhappy about the proliferation of ads for prescription drugs that minimize risk information, hype benefits, make unsupported claims and even fail to acknowledge serious product warnings. Tom Abrams , director of FDA's Division of Drug Marketing, Advertising and Communications (DDMAC) says that the "quality of DTC advertising has declined" in recent years and that the overall tone of ads in less serious. Abrams called on marketers to make ads more educational and useful to consumers. Last year, DDMAC sent manufacturers 12 warning letters, compared with four to five in previous years, and Abrams expects this stepped-up compliance level to continue.
- Jill Wechsler
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Careful Consideration Needed for Management of Acquired (Autoimmune) Hemophilia
May 22nd 2025Patients diagnosed with acquired (autoimmune) hemophilia, a serious and rare bleeding disorder, have high rates of hospital readmissions because of infections and bleeding, as well as high death rates especially among older patients.
Read More